Aprea Therapeutics, Inc. 近日公布,其正在进行的ACESOT-1051剂量递增试验已获得早期临床概念验证数据。该试验旨在评估其Wee1抑制剂候选药物APR-1051。令人鼓舞的是,在首次疗效评估扫描中,已观察到一例患者出现部分缓解,这为药物的抗肿瘤活性提供了初步的积极信号。
Aprea Therapeutics, Inc. 近日公布,其正在进行的ACESOT-1051剂量递增试验已获得早期临床概念验证数据。该试验旨在评估其Wee1抑制剂候选药物APR-1051。令人鼓舞的是,在首次疗效评估扫描中,已观察到一例患者出现部分缓解,这为药物的抗肿瘤活性提供了初步的积极信号。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.